You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Colorcon
McKinsey
Harvard Business School
Boehringer Ingelheim
AstraZeneca

Last Updated: September 28, 2020

DrugPatentWatch Database Preview

Patent: 10,106,620

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,106,620
Title:Blocking CD38 using anti-CD38 F(ab\')2 to protect NK cells
Abstract: Provided herein are methods of inhibiting growth or proliferation of cells expressing CD38 by contacting the CD38-expressing cells with 1) NK cells bound to an anti-CD38 F(ab\').sub.2 fragment and 2) an anti-CD38 antibody, in either order or simultaneously. Also provided herein are methods of treating or inhibiting a hyperproliferative disorder or an autoimmune disorder in a subject by administering to the subject 1) NK cells bound to an anti-CD38 F(ab\').sub.2 fragment and 2) an anti-CD38 antibody, in either order or simultaneously.
Inventor(s): Childs; Richard W. (Rockville, MD), Berg; Maria (Bethesda, MD), Espinoza Calderon; Luis (Bethesda, MD), Sasser; Kate (Spring House, PA), Attar; Ricardo (Spring House, PA)
Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services (Washington, DC) Janssen Biotech, Inc. (Spring House, PA)
Application Number:15/319,344
Patent Claims:see list of patent claims

Details for Patent 10,106,620

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Janssen Biotech DARZALEX daratumumab INJECTABLE;INJECTION 761036 001 2015-11-16   Start Trial The United States of America, as represented by the Secretary, Department of Health and Human Services (Washington, DC) Janssen Biotech, Inc. (Spring House, PA) 2034-06-16 RX Orphan search
Janssen Biotech DARZALEX daratumumab INJECTABLE;INJECTION 761036 002 2015-11-16   Start Trial The United States of America, as represented by the Secretary, Department of Health and Human Services (Washington, DC) Janssen Biotech, Inc. (Spring House, PA) 2034-06-16 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Express Scripts
McKinsey
Moodys
Harvard Business School
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.